-$0.01 Earnings Per Share Expected for AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) This Quarter
Brokerages expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to announce ($0.01) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for AVEO Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at $0.08. AVEO Pharmaceuticals reported earnings of ($0.05) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 80%. The business is expected to issue its next earnings results on Friday, November 8th.
On average, analysts expect that AVEO Pharmaceuticals will report full year earnings of ($0.11) per share for the current financial year, with EPS estimates ranging from ($0.17) to ($0.04). For the next year, analysts anticipate that the firm will post earnings of ($0.15) per share, with EPS estimates ranging from ($0.21) to ($0.10). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow AVEO Pharmaceuticals.
AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.04. AVEO Pharmaceuticals had a negative net margin of 46.69% and a negative return on equity of 37.43%. The business had revenue of $0.70 million for the quarter, compared to analysts’ expectations of $1.78 million.
AVEO stock traded down $0.02 during midday trading on Friday, reaching $0.65. 1,737,321 shares of the company’s stock traded hands, compared to its average volume of 2,834,944. The firm has a 50-day moving average price of $0.69. AVEO Pharmaceuticals has a 52 week low of $0.49 and a 52 week high of $3.59. The stock has a market capitalization of $108.32 million, a price-to-earnings ratio of -3.42 and a beta of 0.78.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. HCR Wealth Advisors purchased a new position in shares of AVEO Pharmaceuticals during the 1st quarter valued at $28,000. Excalibur Management Corp grew its position in shares of AVEO Pharmaceuticals by 363.6% during the 1st quarter. Excalibur Management Corp now owns 51,000 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 40,000 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of AVEO Pharmaceuticals during the 1st quarter valued at $50,000. WealthTrust Axiom LLC grew its position in shares of AVEO Pharmaceuticals by 390.5% during the 1st quarter. WealthTrust Axiom LLC now owns 138,505 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 110,270 shares in the last quarter. Finally, Virtu Financial LLC grew its position in shares of AVEO Pharmaceuticals by 105.5% during the 1st quarter. Virtu Financial LLC now owns 139,585 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 71,667 shares in the last quarter. Hedge funds and other institutional investors own 28.27% of the company’s stock.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Featured Article: Futures Contract
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.